Phase 2Active, not recruiting
Senolytics to Improve Osteoporosis Therapy (SENIOR)
SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial
- Sponsor
- Odense University Hospital (Academic or other)
- Enrolment
- 120 planned
- Conditions
- Osteopenia, Osteoporosis; Age-related Bone Loss
- Interventions
- Dasatinib 100 Mg Oral Tablet; Quercetin 1.250 mg (oral); Nicotinamide Riboside 1g (oral)
- Ages
- adults, older adults
- Registry
- NCT06018467
From the registry
This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and antioxidant therapy on bone.
Primary outcomes
- Bone resorption marker CTX